Trial to Evaluate the Effects of Two Human Milk Oligosaccharides Added to Starter Infant Formula in Healthy Chinese Newborns
Led by Société des Produits Nestlé (SPN) · Updated on 2025-11-28
262
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying healthy male and female term infants in China to evaluate how two human milk oligosaccharides HMOs might positively affect gut bacteria, gut development, gut barrier strength, immune responses, and other growth outcomes. The study is a randomized, controlled, double-blind trial that includes two groups of formula-fed infants and a non-randomized breastfed reference group.
Infants in the two formula-fed groups will receive starter infant formulas either supplemented with the two HMOs or without them. Both formula groups will consume their assigned starter formula freely up to 6 months of age, after which they will switch to a standard follow-up formula until 12 months. The breastfed group will continue receiving breast milk as a reference for comparison.
During the study, researchers will collect fecal samples to analyze gut bacteria, metabolism, immune health markers, gut barrier function, and inflammation at various points up to 12 months of age. They will also assess stool patterns, gastrointestinal symptoms, immune competence, sleep, quality of life, growth, physical exams, illnesses, and medication use. This comprehensive monitoring will help understand the effects of HMOs on infant development over the first year of life.
CONDITIONS
Brief Title
Efficacy of Two HMOs in Chinese Infants
Research Team
Q
Qiaoji Li
J
Joyce Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Healthy male and female infants aged 3 to 14 days at enrollment
Signed informed consent from parent(s) or legal representatives
Parent(s) are legally adults in China
Parent(s)/legal representatives willing and able to comply with study visits and protocol
Parent(s)/legal representatives can be contacted by phone during the trial
Parent(s)/legal representatives have a working freezer
Singleton, full-term birth (37 weeks or more) with birth weight between 2.5 and 4.5 kg
For formula-fed groups: infant exclusively consuming and tolerating cow's milk formula for at least 3 days before enrollment; mother has chosen not to breastfeed
For breastfed group: infant exclusively breastfed since birth (small amounts of other feeds allowed in first 3 days before breastfeeding established); mother plans to continue exclusive breastfeeding to at least 3 months
You will not qualify if you...
Infants needing feeding other than specified in the protocol
Infants receiving 4 or more teaspoons (about 20 g) per day of complementary foods or liquids before enrollment
Infants with medical conditions or histories increasing trial risk or affecting results, including major congenital malformations or systemic infections
Infants currently or previously receiving probiotics or medications/supplements affecting fat digestion, stool, growth, or gastric acid secretion
Infants participating or having participated in another clinical trial since birth
Infants with known or suspected cow's milk protein allergy, lactose intolerance, or soy intolerance/allergy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 12 months
Participants receive starter infant formula orally ad libitum up to 6 months of age, followed by a transition to a standard infant follow-up formula until 12 months of age.
Visits scheduled from enrollment until 12 months of age to monitor growth, health, and biological samples
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Similar Trials
Study of Probiotic Supplement Recovery in Healthy Full-term Newborns with Daily Dosing for 4 Weeks
Evaluating the Effects of a Dietary Supplement on the Gut Microbiome and Health in Healthy Infants A Double-Blind, Randomized, Placebo-Controlled Nutritional Study
A Randomized Controlled Trial Evaluating the Effects of a New Infant Formula with Bioactive Ingredients on Gut Bifidobacterium Levels in Healthy Infants
Trial to Evaluate the Effects of Two Human Milk Oligosaccharides Added to Starter Infant Formula in Healthy Chinese Newborns
Evaluating Growth, Tolerance, and Biomarkers in Healthy Infants Receiving Probiotic and Placebo Dietary Supplements A Randomized, Double-Blind Nutritional Study
Study of Human Milk Oligosaccharides in Infant Formula to Support Gut Microbiota and Immune System Development in Healthy Infants
Study of How a High Fibre and Fermented Food Diet in Breastfeeding Mothers Affects Their Breastfed Babies Gut Health
Study of Two Probiotic Limosilactobacillus Reuteri Strains to Prevent Excessive Crying and Colic in Healthy Newborns
Study of a Probiotic Supplement to Support Gut Health and Immune Development in Healthy Full-Term Newborns
Effects of Lactobacillus Paracasei LPB27 on Gut Microbiota and Immune Development in Healthy Infants Aged 0 to 6 Months
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial.